Drugs that contain Posaconazole
1. Drug name - NOXAFIL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9750822 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US8410077 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US10117951 | MERCK SHARP DOHME | Sulfoalkyl ether cyclodextrin compositions |
Mar, 2029
(6 years from now) | |
| US9358297 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jun, 2031
(8 years from now) | |
| US9023790 | MERCK SHARP DOHME | Posaconazole intravenous solution formulations stabilized by substituted β-cyclodextrin |
Jul, 2031
(8 years from now) | |
| US9493582 | MERCK SHARP DOHME | Alkylated cyclodextrin compositions and processes for preparing and using the same |
Feb, 2033
(10 years from now) | |
Treatment: Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised; Treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older; prophylaxis of invasive aspergillus and candida infections; prophylaxis of invasive aspergillus and candida infections in adults and pediatric patients 2 years of age and older who are severely immunocompromised
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 300MG/16.7ML (18MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.